| 1 |
2023 |
Marzieh Mazinani, Fatemeh Rahbarizadeh. New cell sources for CAR-based immunotherapy, Biomarker Research. 2023; 11: 49.
https://doi.org/10.1186/s40364-023-00482-9 |
| 2 |
2023 |
Mohammad Reza Lahimchi, Faezeh Maroufi, Amirhosein Maali. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy, Cellular Reprogramming. 2023; 25: 195.
https://doi.org/10.1089/cell.2023.0041 |
| 3 |
2025 |
John Anderson, 2025; 77.
https://doi.org/10.1016/B978-0-443-21766-1.00009-6 |
| 4 |
2024 |
Claudia Juraske, Sonia M Krissmer, Evelyn S Teuber, Maria A Parigiani, Juliane Strietz, Daniela Wesch, Dieter Kabelitz, Susana Minguet, Wolfgang W Schamel. Reprogramming of human γδ T cells by expression of an anti-CD19 TCR fusion construct (εTRuC) to enhance tumor killing, Journal of Leukocyte Biology. 2024; 115: 293.
https://doi.org/10.1093/jleuko/qiad128 |
| 5 |
2024 |
Chaozhi Tang, Yuling Zhang. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review, Pathology - Research and Practice. 2024; 262: 155518155518.
https://doi.org/10.1016/j.prp.2024.155518 |
